DGE’S Risk-Based Quality Management Summit
June 3-4th, 2021
DGE’s Risk-Based Quality Management Summit June 3-4th, 2021 On 3rd -4th June 2021, biopharma and medical device companies are invited to attend the Live Streaming of the Risk-Based Quality Management Summit. The event is hosted by Dynamic Global Events (“DGE”), a Life Science Leader in organizing B2B Events. The Global Event Company caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries.
The 2-day event will start with the chairperson’s opening remarks followed by a keynote on World-Class Enterprise Risk Evaluation and Adaptive Monitoring provided Andy Lee, SVP, Head of Global Clinical Trials Operations at Merck Research Laboratories. Experts will share insights proactive risk management, quality my design and data monitoring.
This Summit aims to discuss risk tolerance and agility in clinical trial oversight. The RBQM Summit will provide all the latest information that will help reduce the complexity and costs associated with clinical trials, cutting down the risks involved, to derive the maximum output from the R&D budget. The Risk-Based Quality Management Summit will include two sessions on COVID-19 with Phi Tat, Central Monitoring Manager, Pfizer (NASDAQ: PFE), and Jennifer Goewey, Associate Director, Risk Management-Central Monitoring, Janssen R&D, to address the impact of COVID19 on trials. The Summit will focus on complex issues, including: o How to design a comprehensive RBQM master plan on Streamline a “culture of quality” for proactive risk management to Discern the realities of applying Six Sigma to clinical research to Assess the situation when thresholds are exceeded and whether subsequent data are still valid to Evaluate remote monitoring of data and examine changes in clinical trial landscape post COVID-19 o Exacting a risk-based audit strategy and prepare to ensure inspection readiness The distinguished speaking faculty of the Summit consists of 15 imminent influencers from the pharma industry and risk-management experts.
Andy Lee, Merck Research Laboratories, SVP, Head of Global Clinical Trials Operations; Andy Lawton, Risk-Based Approach Ltd, Consultant; Angela Repa, bluebird bio (NASDAQ: BLUE), Senior Director, Proactive Clinical Excellence; Anne Lawrence, AbbVie (NASDAQ: ABBV), Executive Director Site Management Operations; Celeste Gonzalez, Boston Scientific, Principal Specialist, Clinical Quality Assurance and Compliance; Shawntel Swannack, GSK (NASDAQ: GSK), Central Monitoring, to name a few. In these uncertain times, this Summit offers in depth and fresh perspectives on RBQM. It will provide an opportunity for World-Class Risk Evaluation and Adaptive Integrated Monitoring that will help conserve energy and resources and maintain agility in clinical trial oversight.
For more information regarding the event, please visit https://ibn.fm/6bglf
